The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease

A. Taylor, A. Beerahee, D. Citerone, M. Davy, K. Fitzpatrick, A. Lopez-Gil, F. Stocchi

Research output: Contribution to journalArticle

Abstract

Aims. The aim of this single-blind study was to assess the effect of ropinirole, a novel treatment for Parkinson's disease, on the steady-state pharmacokinetics and safety of digoxin in 10 patients with Parkinson's disease. Methods. There were three parts to the study: digoxin once daily plus placebo three times daily for 1 week; digoxin once daily plus ropinirole three times daily for G weeks, and digoxin once daily plus placebo three times daily for 1 week. Serial blood samples were collected over 24 h at the end of each part of the study for pharmacokinetic assessment. Pre-dose blood samples were collected on specific days throughout the study to assess the attainment of steady-state plasma levels of digoxin. The primary endpoints were AUC(0, τ) and C(max) for digoxin. Results. There was a mean decrease of 10% in digoxin AUC (0, τ) (90% CI: 0.79, 1.01) and a 25% decrease in digoxm C(max) (90% CI: 0.58, 0.97) when ropinirole was co-administered, compared with digoxin alone. C(min) plasma values for digoxin, however, were fairly constant throughout the study (point estimates 0.99, 95% CI: 0.85, 1.15). Changes in trough levels of digoxin are believed to be the most reliable way of assessing steady-state concentrations of digoxin, and therefore the clinical significance of an interaction. Changes in C(max) are too readily influenced by other factors. Conclusions. These results therefore indicate that on pharmacokinetic grounds no dose adjustment is necessary for digoxin co-administered with ropinirole.

Original languageEnglish
Pages (from-to)219-222
Number of pages4
JournalBritish Journal of Clinical Pharmacology
Volume47
Issue number2
DOIs
Publication statusPublished - 1999

Fingerprint

Digoxin
Parkinson Disease
Pharmacokinetics
Area Under Curve
ropinirole
Placebos
Single-Blind Method

Keywords

  • Digoxin
  • Parkinson's disease
  • Pharmacokinetics
  • Ropinirole

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. / Taylor, A.; Beerahee, A.; Citerone, D.; Davy, M.; Fitzpatrick, K.; Lopez-Gil, A.; Stocchi, F.

In: British Journal of Clinical Pharmacology, Vol. 47, No. 2, 1999, p. 219-222.

Research output: Contribution to journalArticle

Taylor, A. ; Beerahee, A. ; Citerone, D. ; Davy, M. ; Fitzpatrick, K. ; Lopez-Gil, A. ; Stocchi, F. / The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. In: British Journal of Clinical Pharmacology. 1999 ; Vol. 47, No. 2. pp. 219-222.
@article{991baa88cd0744a0a09e3f247c30d5f5,
title = "The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease",
abstract = "Aims. The aim of this single-blind study was to assess the effect of ropinirole, a novel treatment for Parkinson's disease, on the steady-state pharmacokinetics and safety of digoxin in 10 patients with Parkinson's disease. Methods. There were three parts to the study: digoxin once daily plus placebo three times daily for 1 week; digoxin once daily plus ropinirole three times daily for G weeks, and digoxin once daily plus placebo three times daily for 1 week. Serial blood samples were collected over 24 h at the end of each part of the study for pharmacokinetic assessment. Pre-dose blood samples were collected on specific days throughout the study to assess the attainment of steady-state plasma levels of digoxin. The primary endpoints were AUC(0, τ) and C(max) for digoxin. Results. There was a mean decrease of 10{\%} in digoxin AUC (0, τ) (90{\%} CI: 0.79, 1.01) and a 25{\%} decrease in digoxm C(max) (90{\%} CI: 0.58, 0.97) when ropinirole was co-administered, compared with digoxin alone. C(min) plasma values for digoxin, however, were fairly constant throughout the study (point estimates 0.99, 95{\%} CI: 0.85, 1.15). Changes in trough levels of digoxin are believed to be the most reliable way of assessing steady-state concentrations of digoxin, and therefore the clinical significance of an interaction. Changes in C(max) are too readily influenced by other factors. Conclusions. These results therefore indicate that on pharmacokinetic grounds no dose adjustment is necessary for digoxin co-administered with ropinirole.",
keywords = "Digoxin, Parkinson's disease, Pharmacokinetics, Ropinirole",
author = "A. Taylor and A. Beerahee and D. Citerone and M. Davy and K. Fitzpatrick and A. Lopez-Gil and F. Stocchi",
year = "1999",
doi = "10.1046/j.1365-2125.1999.00867.x",
language = "English",
volume = "47",
pages = "219--222",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease

AU - Taylor, A.

AU - Beerahee, A.

AU - Citerone, D.

AU - Davy, M.

AU - Fitzpatrick, K.

AU - Lopez-Gil, A.

AU - Stocchi, F.

PY - 1999

Y1 - 1999

N2 - Aims. The aim of this single-blind study was to assess the effect of ropinirole, a novel treatment for Parkinson's disease, on the steady-state pharmacokinetics and safety of digoxin in 10 patients with Parkinson's disease. Methods. There were three parts to the study: digoxin once daily plus placebo three times daily for 1 week; digoxin once daily plus ropinirole three times daily for G weeks, and digoxin once daily plus placebo three times daily for 1 week. Serial blood samples were collected over 24 h at the end of each part of the study for pharmacokinetic assessment. Pre-dose blood samples were collected on specific days throughout the study to assess the attainment of steady-state plasma levels of digoxin. The primary endpoints were AUC(0, τ) and C(max) for digoxin. Results. There was a mean decrease of 10% in digoxin AUC (0, τ) (90% CI: 0.79, 1.01) and a 25% decrease in digoxm C(max) (90% CI: 0.58, 0.97) when ropinirole was co-administered, compared with digoxin alone. C(min) plasma values for digoxin, however, were fairly constant throughout the study (point estimates 0.99, 95% CI: 0.85, 1.15). Changes in trough levels of digoxin are believed to be the most reliable way of assessing steady-state concentrations of digoxin, and therefore the clinical significance of an interaction. Changes in C(max) are too readily influenced by other factors. Conclusions. These results therefore indicate that on pharmacokinetic grounds no dose adjustment is necessary for digoxin co-administered with ropinirole.

AB - Aims. The aim of this single-blind study was to assess the effect of ropinirole, a novel treatment for Parkinson's disease, on the steady-state pharmacokinetics and safety of digoxin in 10 patients with Parkinson's disease. Methods. There were three parts to the study: digoxin once daily plus placebo three times daily for 1 week; digoxin once daily plus ropinirole three times daily for G weeks, and digoxin once daily plus placebo three times daily for 1 week. Serial blood samples were collected over 24 h at the end of each part of the study for pharmacokinetic assessment. Pre-dose blood samples were collected on specific days throughout the study to assess the attainment of steady-state plasma levels of digoxin. The primary endpoints were AUC(0, τ) and C(max) for digoxin. Results. There was a mean decrease of 10% in digoxin AUC (0, τ) (90% CI: 0.79, 1.01) and a 25% decrease in digoxm C(max) (90% CI: 0.58, 0.97) when ropinirole was co-administered, compared with digoxin alone. C(min) plasma values for digoxin, however, were fairly constant throughout the study (point estimates 0.99, 95% CI: 0.85, 1.15). Changes in trough levels of digoxin are believed to be the most reliable way of assessing steady-state concentrations of digoxin, and therefore the clinical significance of an interaction. Changes in C(max) are too readily influenced by other factors. Conclusions. These results therefore indicate that on pharmacokinetic grounds no dose adjustment is necessary for digoxin co-administered with ropinirole.

KW - Digoxin

KW - Parkinson's disease

KW - Pharmacokinetics

KW - Ropinirole

UR - http://www.scopus.com/inward/record.url?scp=0033050896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033050896&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2125.1999.00867.x

DO - 10.1046/j.1365-2125.1999.00867.x

M3 - Article

C2 - 10190658

AN - SCOPUS:0033050896

VL - 47

SP - 219

EP - 222

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 2

ER -